CLOSE

Soft Tissue Sarcoma

HIGHLIGHTS

The scope of competence of the division includes all clinical and research aspects regarding patients with soft tissue sarcomas and rare cancers.

-  Dignostic radiology, for defining the local extension and morphological characteristics of the disease

-Pathological and molecular diagnosis, for defining the class of risk

-Local treatment, neoadjuvant and adjuvant treatment

-Treatment of advanced disease

-Second opinion

 

Our Activities

All clinical aspects are managed as part of the Multidisciplinary Group, consisting of surgeons, oncologists, radiotherapists, pathologists, radiologists, interventional radiologists, physiotherapists, the cancer psychologist, and potentially involves cross-collaboration with the reconstructive plastic surgeon, thoracic surgeon, neurologist, gynaecologist. 

In managing the therapeutic strategy, which is often based on a combination of surgery and radiotherapy or surgery/radiotherapy/chemotherapy, particular attention is paid to preservative surgery of the limbs, which uses loco-regional treatments, functional reconstruction techniques and plastic reconstruction and pre- and post-operative treatments. Patients with these diseases are offered a vast range of treatment options, in line with international standards, and the option for innovative treatments as part of clinical studies.        

Primary aims

• To promote a European or global programme of NGS and molecular screening in sarcomas, leading to new drug development and discovery

•      Combined therapy studies:       
Immunotherapy with conventional x-ray therapy or with heavy particles
Immunotherapy with target therapy 

• Preoperative treatment in high grade sarcomas 

• Immunosignature of sarcomas of the soft parts (in collaboration with INT and ICH)

• Ablative radiotherapy (radio surgery and stereotactic radiotherapy) in the oligometastatic patient 

Active participation of IEO in the activities of the Italian Sarcoma Group (ISG), CTOS (Connective Tissue Oncology Society) and EORTC.

  • Our staff
     

    Soft Tissue Sarcoma

    Program co-director

    Elisabetta Pennacchioli

    Staff Soft Tissue Sarcoma

  • clinical research

    Clinical research in this phase will be oriented especially towards participation in multicentre studies, both academic and sponsored, having the following principal interests:

     

    • – Identification of dedicated clinical research data managers and nurses, with training and interaction with the clinical research team

    – Optimisation of treatments integrated with surgery and radiotherapy differentiated by isotype or disease site in patients with high-risk localised disease
    – Development of systemic treatments with new drugs or for evaluating the activity/efficacy of known drugs not studied for sarcoma

    – Evaluation of possible new areas of research (identification of targets, proposals for collaborative studies), new local therapy approaches in collaboration with interventional radiology and participation in multicentre studies for evaluating the genetics/families of patients with sarcoma

     

    Specifically: 

    – Preoperative treatment in high-risk localised disease, comparing a standard chemotherapy with a chemotherapy targeted by isotype, as part of a study coordinated by Italian, Spanish and French Sarcoma Groups (already active).

    – Evaluation, within studies under development, of the role of treatments with monoclonal antibodies (e.g. Ab-PDGFRA Olaratumab, phase II submitted to ASCO with doubling of OS at 23 months in metastatic sarcomas, rapid FDA approval scheduled), chemotherapy in precise subgroups (e.g. eribulin in liposarcomas, alkylating oral medicines in EORTC studies), target drugs (e.g. regorafenib in STS, NTRK inhibitors, following evaluation via pilot studies of NTRK mutations in various subtypes of soft tissue sarcoma).

    – Evaluation of precautionary treatment of high-risk patients with GIST with schemes implemented over the standard (masitinib)

    – National data collection via the Italian Sarcoma Group as part of radiation-induced angiosarcomas for possible creation of a study of a precautionary chemotherapy treatment in breast angiosarcoma

    – Collaborative evaluation with interventional radiology for the integration of chemoembolisation/thermoablation with systemic therapy in the treatment of patients with GIST and soft tissue sarcoma (potential development of a phase 2 protocol to validate the choice of RAI in place of surgery in metastatic patients)

     

  • basic research

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

facebook IEO googleplus IEO twitter IEO pinterest IEO vimeo IEO